Aiming at the eye medicine market, "Hermes" manufacturer of eye potions has a new action

Pharmaceutical Network Corporate NewsMay 28, Japan's Satian Pharmaceutical Eye Drop Shigh High-Speed Filling Line Launch Ceremony was held in Suzhou Industrial Park, China, meaning that the pharmaceutical company's high-speed filling line of eye drops is officially put into commercial useit is understood that The Company is a Japanese manufacturer focused on ophthalmology medicine, and its production of eye drops, once known as "hermes in the eye potion world."According to the person in charge of the Suzhou plant of Ginseng Pharmaceuticals, after this official commercial production, the production speed of the Suzhou plant will be increased nearly 6 times, the production capacity will be expanded by at least 3 times in a short period of time, to achieve a qualitative leapIn addition, all of these drugs will be launched in the Chinese marketin addition to announcing the production of high-speed filling line of eye drops, The company is also currently in Suzhou Industrial Park to build a large ophthalmological pharmaceutical base, a total construction area of about 120,000 square metersWhen the new plant is completed, it will have an annual production capacity of 1 billion unitsThe Suzhou plant is expected to be officially completed after 2025behind its new moves, is undoubtedly aimed at China's huge eye drug marketData show that in 2017, China's ophthalmology market size of 86.6 billion yuanWith the aging of the population, the change of people's living habits, the incidence of eye diseases in China is rising, patient awareness is also strengthening, the industry is expected to 2018-2022, China's eye care market will continue to grow at about 14% growth, the total size is expected to exceed 100 billion yuanreported that the Chinese business of Ginseng Pharmaceuticals has grown rapidly in recent years, accounting for 60% of the total in AsiaChina accounts for 9% of total global sales in fiscal 2019, according to the dataat present, not only the company, But also Novartis Pharmaceuticals of Switzerland, The United States, Alcon and other foreign-funded enterprises are also in China's eye medicine market layoutAs early as 1995, Elcon entered the Chinese market as a legal entityIn 2012, Swiss drugmaker Novartis announced that its eye drug Lucentis had been approved by Chinese regulators Data show that Lucentis is used to treat wet geriatric macular degeneration The disease can cause damage to the macular (part of the center of the eye's retina), which can lead to blindness and severe vision loss Novartis estimates that china adds more than 300,000 new cases each year at the same time, the domestic ophthalmology drug companies Zhuhai Yusheng, Chengdu Kanghong, the public pharmaceutical industry, Xingqi eye medicine, etc are also expanding production For example, in 2016, Zhuhai Yusheng announced that it had entered into a distribution agreement with Elektron for the ophthalmology medical device "Macular Pigment Scanner II", a subsidiary that has a distributor in mainland China This will help the Group expand its product range and increase its market share in the ophthalmology medical device market in addition, Chengdu Kanghong in 2017 to invest in IOPtima company in China to obtain the distribution rights of the product, expand the ophthalmology product line, and enter the field of eye equipment and consumables, while opening the company's innovative solutions in the field of glaucoma treatment; but because of the domestic ophthalmology drug companies started late, so the gap with foreign-funded enterprises is larger Mi net data show that in 2018, the domestic key provinces and cities of public hospitalophthalmology drug use, imported drugs accounted for more than 60% of the market share, while domestic drugs accounted for only about 30% Top5 in the ophthalmology market is 25.35 per cent for Novartis of Switzerland, 14.24 per cent for Ginseng Pharmaceuticals, 6.32 per cent for Ursapharm in Germany and 4.71 per cent for Shenyang Xingqi eye medicine.